|
Market Closed -
Other stock markets
|
After hours 01:00:00 | |||
| 221.23 USD | -0.56% |
|
225.60 | +1.97% |
| 06-17 | Medincell Shares Plunge Following Annual Results |  |
| 06-16 | Allergan Aesthetics Receives Fda Approval for Skinvive by Juvederm for Improvement of Neck Appearance | CI |
Business description: AbbVie Inc.
Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Number of employees: 57,000
Sales by Activity: AbbVie Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Innovative Medicines and Therapies | 56.2B | 58.05B | 54.32B | 56.33B | 61.16B |
Geographical breakdown of sales: AbbVie Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 43.51B | 45.71B | 41.88B | 43.03B | 46.6B |
ALL Other Countries | 4.76B | 4.84B | 5.04B | 5.45B | 5.76B |
Germany | 1.22B | 1.34B | 1.27B | 1.46B | 1.74B |
Japan | 1.09B | 956M | 1.01B | 1.12B | 1.27B |
Canada | 1.4B | 1.16B | 1.08B | 1.09B | 1.22B |
China | 857M | 912M | 950M | 917M | 1.01B |
France | 936M | 787M | 780M | 776M | 806M |
United Kingdom | 497M | 462M | 417M | 522M | 626M |
Spain | 519M | 506M | 501M | 528M | 609M |
Italy | 506M | 444M | 484M | 511M | 580M |
Brazil | 368M | 430M | 439M | 464M | 478M |
Australia | 533M | 508M | 472M | 463M | 459M |
Executive Committee: AbbVie Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 30/06/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 22/06/2022 |
Linda Ray
CTO | Chief Tech/Sci/R&D Officer | - | 29/02/2024 |
Latif Akintade
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/2023 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | 54 | 31/12/2002 |
Composition of the Board of Directors: AbbVie Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 31/12/2012 |
William Burnside
BRD | Director/Board Member | 74 | 31/12/2012 |
Edward Rapp
BRD | Director/Board Member | 68 | 31/12/2012 |
Robert Michael
CHM | Chairman | 55 | 30/06/2025 |
Rebecca Roberts
BRD | Director/Board Member | 73 | 31/12/2017 |
Thomas Freyman
BRD | Director/Board Member | 71 | 07/05/2020 |
Brett Hart
BRD | Director/Board Member | 57 | 31/12/2015 |
Melody Meyer
BRD | Director/Board Member | 68 | 31/12/2016 |
| Director/Board Member | 72 | 31/12/2012 | |
Jennifer Davis
BRD | Director/Board Member | 54 | 10/10/2023 |
Holdings: AbbVie Inc.
| Name | Stocks | % | Valuation |
|---|---|---|---|
XILIO THERAPEUTICS, INC. 5.19% | 310,561 | 5.19% | 3 M $ |
ABBVIE INC. 0% | 5,935 | 0% | 1 M $ |
| 1,855,871 | 4.44% | 186 $ |
Company details: AbbVie Inc.
Group companies: AbbVie Inc.
| Name | Category and Sector |
|---|---|
AbbVie Biopharmaceuticals GmbH Taiwan Branch
 AbbVie Biopharmaceuticals GmbH Taiwan Branch Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focused on developing advanced therapies |
Pharmaceuticals: Major
|
Allergan Pharmaceuticals Ireland ULC
 Allergan Pharmaceuticals Ireland ULC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products |
Pharmaceuticals: Major
|
Allergan Pharmaceuticals Ireland ULC
Allergan Pharmaceuticals Ireland ULC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products |
Pharmaceuticals: Major
|
Aptalis Pharma Canada ULC
 Aptalis Pharma Canada ULC Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products |
Pharmaceuticals: Major
|
Aptalis Pharma Canada ULC
Aptalis Pharma Canada ULC Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.56% | -1.65% | +19.27% | +59.57% | 391B | |
| -0.94% | -2.14% | +40.54% | +148.38% | 992B | |
| -0.42% | -1.80% | +53.69% | +42.60% | 564B | |
| +0.34% | +0.68% | +24.66% | +16.53% | 330B | |
| +0.20% | -0.78% | +27.72% | +15.68% | 280B | |
| +0.26% | -0.10% | +27.85% | +33.65% | 279B | |
| -0.06% | +0.96% | -40.88% | -47.31% | 196B | |
| -1.78% | +1.16% | +17.79% | +48.77% | 184B | |
| -1.40% | +3.27% | +16.16% | +59.08% | 156B | |
| -0.46% | +1.25% | +8.00% | -35.30% | 148B | |
| Average | -0.44% | +0.50% | +19.48% | +34.16% | 351.9B | |
| Weighted average by Cap. | -0.49% | -0.42% | +28.60% | +61.77% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ABBV Stock
- Company AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition